AUTHOR=Zhang Bingxin , Wang Quanqiang , Lin Zhili , Zheng Ziwei , Zhou Shujuan , Zhang Tianyu , Zheng Dong , Chen Zixing , Zheng Sisi , Zhang Yu , Lin Xuanru , Dong Rujiao , Chen Jingjing , Qian Honglan , Hu Xudong , Zhuang Yan , Zhang Qianying , Jin Zhouxiang , Jiang Songfu , Ma Yongyong
TITLE=A novel glycolysis-related gene signature for predicting the prognosis of multiple myeloma
JOURNAL=Frontiers in Cell and Developmental Biology
VOLUME=11
YEAR=2023
URL=https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2023.1198949
DOI=10.3389/fcell.2023.1198949
ISSN=2296-634X
ABSTRACT=Background: Metabolic reprogramming is an important hallmark of cancer. Glycolysis provides the conditions on which multiple myeloma (MM) thrives. Due to MM’s great heterogeneity and incurability, risk assessment and treatment choices are still difficult.
Method: We constructed a glycolysis-related prognostic model by Least absolute shrinkage and selection operator (LASSO) Cox regression analysis. It was validated in two independent external cohorts, cell lines, and our clinical specimens. The model was also explored for its biological properties, immune microenvironment, and therapeutic response including immunotherapy. Finally, multiple metrics were combined to construct a nomogram to assist in personalized prediction of survival outcomes.
Results: A wide range of variants and heterogeneous expression profiles of glycolysis-related genes were observed in MM. The prognostic model behaved well in differentiating between populations with various prognoses and proved to be an independent prognostic factor. This prognostic signature closely coordinated with multiple malignant features such as high-risk clinical features, immune dysfunction, stem cell-like features, cancer-related pathways, which was associated with the survival outcomes of MM. In terms of treatment, the high-risk group showed resistance to conventional drugs such as bortezomib, doxorubicin and immunotherapy. The joint scores generated by the nomogram showed higher clinical benefit than other clinical indicators. The in vitro experiments with cell lines and clinical subjects further provided convincing evidence for our study.
Conclusion: We developed and validated the utility of the MM glycolysis-related prognostic model, which provides a new direction for prognosis assessment, treatment options for MM patients.